Angiotensin Receptor Blockers (ARBs): Mechanism, Renal Protection and Precautions

Pharmacology education review. Updated 10 November 2026. This is not an individual prescribing protocol; follow current local guidelines and product labeling.

Overview

Angiotensin II receptor blockers (ARBs) inhibit AT1-receptor signaling, lowering vasoconstriction, aldosterone release and sodium retention. They are used for hypertension, albuminuric chronic kidney disease (CKD) and selected heart-failure or post-infarction indications. Clinical benefits and approved indications vary among individual agents [1–3].

Classification and mechanisms

Losartan, valsartan, candesartan, irbesartan, olmesartan and telmisartan are orally administered AT1 receptor antagonists. Most block AT1 responses without inhibiting angiotensin-converting enzyme; consequently, they cause less bradykinin-mediated cough than ACE inhibitors. AT1 blockade may increase circulating angiotensin II, which can stimulate unblocked AT2 receptors, but clinical effects depend on context [1].

Pharmacokinetics

Losartan is metabolized in part by CYP2C9 and CYP3A4 to a longer-acting active metabolite. Candesartan cilexetil and olmesartan medoxomil are prodrugs hydrolyzed to active agents. Valsartan has limited CYP metabolism. Half-life, tissue distribution, excretion and renal/hepatic dose considerations differ by medicine, so do not apply uniform dose schedules across the class [1].

Evidence-based renal indications

KDIGO 2024 recommends an ACE inhibitor or ARB for adults with CKD and severely increased albuminuria (A3) without diabetes and with moderately-to-severely increased albuminuria (A2/A3) with diabetes, with additional conditional advice for A2 without diabetes. Use the highest approved tolerated dose when appropriate. Recheck blood pressure, serum creatinine and potassium within 2–4 weeks after starting or increasing therapy, adjusted for individual risk [2].

Safety and interactions

Hyperkalemia, symptomatic hypotension and transient creatinine elevation may occur, especially with volume depletion, NSAIDs, advanced CKD or renal artery stenosis. A creatinine rise of up to 30% may be tolerated after evaluation; greater rises warrant assessment for AKI or renovascular disease. Avoid routine ACE inhibitor plus ARB or direct renin inhibitor combinations. ARBs are contraindicated during pregnancy because of fetal kidney injury risk; review pregnancy plans proactively. Caution with potassium supplements, spironolactone and trimethoprim [1,2].

Practical monitoring

Measure baseline kidney function and potassium, assess hydration, review other medicines and recheck after titration. Hyperkalemia may sometimes be managed with medication review, diet measures or potassium-lowering therapies rather than automatically stopping a beneficial ARB [2].

References

  1. Brunton LL, Knollmann BC, editors. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 14th ed. McGraw Hill; 2023.
  2. Kidney Disease: Improving Global Outcomes (KDIGO). KDIGO 2024 clinical practice guideline for evaluation and management of chronic kidney disease. Kidney Int. 2024;105:S117–S314. Available from: https://kdigo.org/wp-content/uploads/2024/03/KDIGO-2024-CKD-Guideline.pdf
  3. Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for management of heart failure. Available from: https://www.jacc.org/doi/full/10.1016/j.jacc.2021.12.012
Medical & AI Disclaimer

The information provided on Sumathi Publications is for general educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional regarding any medical condition or treatment decision.

We strive to keep our content accurate and up to date; however, some content may be created or assisted using artificial intelligence (AI) and may contain errors or omissions. All information should be independently verified before use. Reliance on any content provided by Pharmacology Mentor is at your own risk.

Leave a Reply

Your email address will not be published. Required fields are marked *